C4 Therapeutics, Inc. — Director's Dealing 2020

Oct 7, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2020-10-06

Reporting Person: Prokupets Elena (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-10-06	Common Stock	C	118574	—	Acquired	118574	Indirect
2020-10-06	Common Stock	C	592873	—	Acquired	592873	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-10-06	Series A Preferred Stock	$	C	1000000	Disposed		Common Stock (118574)	Indirect
2020-10-06	Series A Preferred Stock	$	C	5000000	Disposed		Common Stock (592873)	Indirect

Footnotes

F1: Each share of Series A Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F2: Shares held by ERP Business Holdings, LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein.